FOUNDIN-PD

Foundational Data Initiative for Parkinson's Disease

Conceptual Framework

We see enormous opportunity in the translation of genetic factors to a functional understanding of Parkinson's disease (PD) by unbiased data driven approaches. We will create a public atlas of molecular phenotypes derived from induced pluripotent stem (iPS) lines with a broad range of genetic risk. These data will define molecular networks that are perturbed in disease, providing disease insight, therapeutic targets and relevant readouts for interventional testing. Our intent is to be flexible, changing and augmenting assays, endpoints as needed/requested.

Objectives

Culture and purify of dopaminergic (DA) neurons from 100 iPS lines obtained from the Parkinson’s Progression Markers Initiative (http://www.ppmi-info.org/), and assess their assess transcriptional and epigenetic activity.

Integrate data into ordered, actionable networks across molecular outcomes. Compare networks across monogenic lines and those characterized for complex genetic risk.

Create a publicly facing resource that facilitates the use of these data and affords the development of iteratively improving biological and analytical methods.

path2pd

FOUNDIN-PD is part of The Michael J. Fox Foundation’s PATH to PD program. Learn more at www.michaeljfox.org/pathtopd.

TEAM

Andrew Singleton, Ph.D.

Principal Investigator

Peter Heutink, Ph.D.

High content molecular assays and iPS lines

Steve Finkbeiner, M.D., Ph.D.

High content imaging

Mark Cookson, Ph.D.

High content molecular assay, target investigation

Kendall van Keuren Jensen, Ph.D.

Transcriptomics, RNA analysis

David W. Craig, Ph.D.

Data Integration, Bioinformatics

Mike Nalls, Ph.D.

Network creation, Data science

J. Raphael Gibbs, Ph.D

Analysis, Computational Biology

Contact us

Please enter your name.
Please enter a message.
MJFF_horiz_RGB_logo